Global market entry ARC-EX has CE Mark approval and ongoing US commercialization, supported by ONWARD's Eindhoven HQ and expanding US presence. This creates a clear opportunity to target hospitals, spine and neuro-rehab centers, and neuromodulation clinics with ARC-EX as a programmable spinal stimulation therapy.

Parkinson's trials Early feasibility funding for ARC-IM in Parkinson's disease signals a near-term sales lane to neurology and movement disorder centers. Engage trial sites to drive implant programs, collect evidence, and establish reference centers for broader adoption.

Academic partnerships Existing collaboration with EPFL/CHUV and Lausanne Science Center can accelerate clinician engagement and clinical trials, producing clinician champions and compelling case studies to shorten sales cycles in target markets.

Funding momentum Recent financing activity and leadership expansion indicate capacity to scale the commercial and clinical education teams, enabling multi-site deployments, larger procurement deals, and robust post-install service offerings.

Integrated solutions ARC-IM and ARC-EX provide implantable and external options that can be bundled with training, system programming, and ongoing maintenance, aligning with rehabilitation workflows and providing higher ASP through comprehensive solutions.